Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229681 | 0.88 | HRH3 (0.43) | FLT1KDRHRH3PTGER1GSK3B | |
| SCHEMBL13229621 | 0.86 | BCL2 (0.46) | HRH3 | |
| SCHEMBL13229673 | 0.86 | HRH3 (0.56) | KDRHRH3PTGER1GSK3B | |
| SCHEMBL13229690 | 0.85 | KDR (0.44) | FLT1KDRHRH3PDGFRBKIT | |
| SCHEMBL15127617 | 0.81 | FLT1 (0.45) | FLT1KDRHRH3GSK3B | |
| SCHEMBL2792943 | 0.81 | GSK3B (0.53) | KDRHRH3PTGER1GSK3B | |
| SCHEMBL13262010 | 0.80 | FLT1 (0.46) | FLT1KDRGUSBGSK3BRAPGEF4 | |
| SCHEMBL13229617 | 0.79 | NPC1 (0.46) | HRH3PTGER1 | |
| SCHEMBL13229627 | 0.79 | HRH3 (0.44) | FLT1KDRHRH3PTGER1GSK3B | |
| SCHEMBL2792715 | 0.77 | HRH3 (0.39) | HRH3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492415-B2 | Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV) | YALE UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492415-B2 | Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV) | YALE UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | YALE UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | YALE UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| WO-2009005811-A1 | NOVEL AZOLES AND RELATED DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) IN ANTIVIRAL THERAPY (HIV) | YALE UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | OXA1L, POLRMT, PNP | FLT1 1254/4885KDR 2712/4885HRH3 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.